C3 Jian Announces Appointment of Biotech Veteran H. Stewart Parker as New Board Chair

LOS ANGELES, California — March 1, 2016 — C3 Jian, Inc., a privately-held clinical stage biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, announced that H. Stewart Parker has been appointed as new Chair of the Board of Directors, effective immediately. The Company’s former and Founding Chairman, Mr. Jim Garrison, will remain an active member of the Board.

Ms. Parker, who has over 30 years of industry experience, has served on C3J’s Board of Directors since 2010 and is the Principal of Parker BioConsulting. Previously she was Chief Executive Officer of the Infectious Disease Research Institute in Seattle, where she served from 2011 to 2014. Stewart was the Founding President and CEO of Targeted Genetics Corporation, a Seattle-based biotechnology company formed in 1992 to develop gene-based treatments for acquired and inherited disease. Prior to Targeted Genetics, Stewart held various positions at Immunex Corporation from 1981-1992, ending her tenure there as Vice President of Corporate Development, and President and CEO of its subsidiary Receptech Corporation. Ms. Parker currently serves on the board of several companies including Nexgenia, Sangamo BioSciences, Impel NeuroPharma, and Oncogenex Pharmaceuticals. She is also a past Board member of the Seattle Branch of the Federal Reserve Bank of San Francisco.

“We are extremely pleased to welcome Stewart as our new Chair,” stated Todd R. Patrick, President and CEO. “Stewart’s long history in the biotechnology sector will be invaluable as we begin to examine our definitive Phase 2 data and plan for Phase 3 studies with our lead product, while at the same time prioritizing our pipeline programs resulting from our pathogen specific technology platform.”

The Company’s lead program, C16G2, is the first peptide therapeutic derived from the proprietary platform technology referred to as STAMPs (Specifically Targeted Antimicrobial Peptides). STAMP technology specifically targets pathogenic bacteria, to correct dysbiosis of microbiome communities. The result is a microbiome reengineered to restore a healthy ecology with the potential for a lasting therapeutic benefit. C16G2, which targets the specific elimination of Streptococcus mutans, is being developed for the prevention of dental caries under an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 2 multi-center clinical trials. C3J’s other microbiome program is being developed for Clostridium difficile infection using an orally-administered formulation to deliver a STAMP to the regions of the lower GI tract.

“It is an exciting time to assume the Chair position at C3J,” stated Ms. Parker. “Todd and his team have done a remarkable job advancing the programs and financing the Company, and I look forward to working with them in my new role. On behalf of the Board, I also want to thank Jim Garrison for navigating the Company to this stage of development. I am pleased that Jim will remain a colleague on the Board with me.”

About C3 Jian, Inc.
C3 Jian is a clinical stage biotechnology company focused on improving human health through the development and commercialization of targeted, pathogen-specific antimicrobials (STAMPs) that treat and prevent diseases caused by microbial dysbiosis. The proprietary STAMP platform technology has potential applications to a variety of bacterial infections, and disorders, particularly related to the human microbiome. C3 Jian is based in Los Angeles, California. For more information, please visit www.c3-jian.com.

Media Contact: Todd Patrick (T) 310.665.2928 x242, (Email) tpatrick@c3-jian.com or Pierre Kyme (T) 310.665.2928 x234, (Email) pkyme@c3-jian.com.

Leave a Reply